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Abstract 
Objective: To evaluate the contributions of autophagic, necrotic and apoptotic cell death 
mechanisms after neonatal cerebral ischemia and hence define the most appropriate 
neuroprotective approach for post-ischemic therapy.  
Methods: Rats were exposed to transient focal cerebral ischemia on postnatal day 12. 
Some rats were treated by post-ischemic administration of pan-caspase or autophagy 
inhibitors. The ischemic brain tissue was studied histologically, biochemically and 
ultrastructurally for autophagic, apoptotic and necrotic markers. 
Results: Lysosomal and autophagic activities were increased in neurons in the ischemic 
area from 6-24h post-injury, as shown by immunohistochemistry against LAMP1 and 
cathepsin D, by acid phosphatase histochemistry, by increased expression of 
autophagosome-specific LC3-II and by punctate LC3 staining. Electron microscopy 
confirmed the presence of large autolysosomes and putative autophagosomes in 
neurons. The increases in lysosomal activity and autophagosome formation together 
demonstrate increased autophagy, which occurred mainly in the border of the lesion, 
suggesting its involvement in delayed cell death. We also provide evidence for necrosis 
near the centre of the lesion and apoptotic-like cell death in its border, but in 
nonautophagic cells. Post-ischemic intracerebro-ventricular injections of autophagy 
inhibitor 3-methyladenine strongly reduced the lesion volume (by 46%) even when given 
more than 4 hours after the beginning of the ischemia, whereas pan-caspase inhibitors, 
Z-VAD-fmk and Q-VD-OPH, provided no protection.  
Interpretation: The prominence of autophagic neuronal death in the ischemic 
penumbra, and the neuroprotective efficacy of post-ischemic autophagy inhibition 
indicate that autophagy should be a primary target in the treatment of neonatal cerebral 
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ischemia. 
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Peri- or neonatal stroke is a major cause of brain injury and leads to serious motor and 
cognitive disabilities1. Cell death due to cerebral ischemia has generally been attributed 
to necrosis and apoptosis, and most research on stroke has focused on them. Attempts 
at neuroprotection have likewise targeted apoptosis and necrosis, particularly apoptosis, 
but with only limited success2-5.  
Other types of cell death exist, including autophagic, or “type 2”, cell death, 
characterized by numerous autophagic vacuoles. Autophagy is a physiological process 
by which the cell eliminates damaged organelles, toxic agents and long lived proteins by 
degradation in lysosomes6. It thus contributes to the well-being of cells, and can play a 
crucial pro-survival role by restoring intracellular energetic stores during nutrient 
deprivation. But excessive autophagy can promote cell death. Different autophagic 
mechanisms coexist in the same cell, but only one of them, macroautophagy (hereafter 
called autophagy), has been demonstrated to contribute to cell death7-8. In neurons, 
autophagy is enhanced in several conditions including nutrient starvation, development 
and neurodegeneration9. Autophagic cell death occurs in neurons during normal 
development and excitotoxicity10-13 and there is increasing evidence that autophagy may 
be involved in mediating neuronal death in cerebral ischemia14-17. To develop optimal 
neuroprotective strategies in neonatal stroke research, it is important to understand all 
the cell death mechanisms involved, including autophagy. 
Since more than 80% of neonatal strokes involve the middle cerebral artery18, we 
here employ a model of middle cerebral artery occlusion19. We used P12 rats, whose 
brain development corresponds to that of newborn humans1. We show that ischemia 
provokes all three kinds of cell death mechanisms: apoptotic, necrotic and autophagic. 
Caspase inhibition was not neuroprotective, but inhibition of autophagy with 3-
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methyladenine gave strong neuroprotection with a therapeutic window of at least 3h 
after the end of the ischemic insult, opening the way to new neuroprotective strategies in 
neonatal stroke research. Preliminary results have been published in abstracts20-21.  
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Materials and Methods 
 
Focal ischemia model  
All animal procedures were in compliance with the directives of the Swiss Academy of 
Medical Science and were authorized by the veterinary office of the Canton of Vaud. 
Anesthesia was induced with 2.5% isoflurane in a chamber and maintained during the 
operation with a mask using 2.5% isoflurane. Middle cerebral artery occlusion was 
performed in 12 day old male Sprague-Dawley rats according to the protocol of 
Renolleau et al. (1998)19 with modifications. Briefly, the main (cortical) branch of the left 
middle cerebral artery was electrocoagulated just below its bifurcation into frontal and 
parietal branches. The left common carotid artery was then occluded by means of a clip 
for 90min., during which time the rat pups were maintained at 37°C in the induction 
chamber (2.5% isoflurane). The arterial clip was then removed and the restoration of 
carotid blood flow was verified under a dissecting microscope before the skin incision 
was closed. Rat pups were transferred back to their mothers until sacrifice.  
 
Drug administration 
3-methyladenine (3-MA) was obtained from Sigma (St. Louis, MO, USA). Intra-
cerebroventricular (icv) injections were performed in the contralateral ventricle with 2µl 
of a 30mg/ml solution prepared in saline (0.9% NaCl) or with saline alone (n=17). Rats 
were injected either at the beginning of reperfusion (n=9), 3h (n=7) or 6h (n=6) later.  
Quinoline-Val-Asp(ome)-Ch2-O-phenoxy (Q-VD-OPh) (MP Biochemicals, Illkrich, 
France) was dissolved in DMSO (50mM stock solution) and further diluted with sterile 
PBS. Intra-peritoneal injections (ip) were performed with either 1mg/kg Q-VD-OPh (n=6) 
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or with vehicle containing the same percentage of DMSO in PBS (phosphate-buffered 
saline). Another group of animals were injected icv in the contralateral ventricle at the 
beginning of reperfusion with 1.3µg of Q-VD-OPh, 2µl of a 1.25mM solution (n=6), 
prepared in PBS containing final DMSO concentration of 2.5%. Control animals were 
injected with 2.5% DMSO in PBS.  
Carbobezoxy-Valyl-Alanyl-Aspartyl(ome)-fluoromethylketone (Z-VAD-fmk) 
(Sigma, St. Louis, MO, USA) was prepared as a 20mM stock solution in DMSO. 
Different doses of Z-VAD-fmk (500ng, n=5; 160ng, n=5; 80ng, n=8) were dissolved in 
2µl of 0.9% saline and injected icv in the contralateral ventricle at the beginning of 
reperfusion. Control animals were treated with a saline solution containing the same 
percentage of DMSO.  
 
Statistics 
Normality was first tested. When the distribution was normal in all groups (experiments 
on caspases inhibition), one-way ANOVA was used followed by a t-test (one-tailed, 
unpaired). When the normality criterion was not satisfied (experiments with 3-MA), the 
nonparametric Kruskal-Wallis H-test was performed (p=0.0065) followed by a Mann-
Whitney U-test (one-tailed), (p<0.01 for 3-MA 0h and +3h as compared with saline group 
and p=0.4532 for +6h group). 
 
Measurement of infarct volume 
Pups were heavily anesthetized with sodium pentobarbital and perfused intracardially at 
different times after the beginning of the reperfusion with 4% paraformaldehyde in 0.1M 
PBS (pH 7.4). Brains were removed, placed in PBS 30% sucrose in PBS for about 15h 
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at 4°C and then frozen in isopentane (-40°C). Cryostat coronal sections of 50µm were 
stained with cresyl violet. The outline of the infarct was traced in each tenth slice using a 
computer-microscope system equipped with the Neurolucida program (MicroBrightField) 
and the infarct volume calculated with Neuroexplorer (MicroBrightField). Infarct surfaces 
were also plotted along the rostro-caudal axis. Animals treated with 3-MA, Q-VD-OPh 
and Z-VAD-fmk were sacrificed 24 hours after the beginning of reperfusion and 
examined as described previously. 
 
Immunohistochemistry, electron microscopy and Western blots 
The detailed experimental methods concerning immunohistochemistry, electron 
microscopy and Western blots are described in the Supplemental Methods section.  
 
Histochemical staining for lysosomal enzymes 
At different times following ischemia, animals were anesthetized with sodium 
pentobarbital (6mg/100mg body weight, ip) and perfused intracardially with 2% 
glutaraldehyde and 1% paraformaldehyde diluted in cacodylate buffer (0.1M, pH 7.4). 
Brains were removed and post-fixed in the same fixative solution overnight at 4°C, then 
washed three times in 0.1M cacodylate buffer (pH 7.3). Coronal vibratome sections (30-
50µm thick) were done cut and stained as described below. 
Acid phosphatase histochemistry - Coronal brain sections were treated for acid 
phosphatase histochemistry with several modifications of Gomori's sodium β-
glycerophosphatase method22. Briefly, after several washes in distilled water, sections 
were incubated for 2h at 37 °C in 0.01M Na-β-glycerophosphate and 8 µM lead nitrate in 
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sodium acetate buffer (50mM, pH 5). The incubation solution had been filtrated before 
use and was kept for 1h at 37 °C. After incubation, sections were rinsed in distilled water 
and immersed in ammonium sulphide (0.5%) for 30s, rinsed again and mounted in 
fluorsave. Controls were performed using sodium fluoride to verify the labeling 
specificity. No staining was detected in any of these controls.  
β-N-acetylhexosaminidase histochemistry - The histochemical method for β-
hexosaminidase was performed as previously described23. Briefly, sections were 
washed in distilled water and then incubated for 1h at 37 °C in Fast red violet salt 
solution (0.63M ethylene glycol monomethyl ether, 1% polyvinyl pyrrolidone, 0.1M citric 
acid-citrate buffer pH 4.4, 1.6M sodium chloride, 2.7mM Fast red violet LB salt (Sigma)) 
using 0.5mM Naphthol-AS-BI-N-acetyl-β-D-glucosaminide (Sigma) as the substrate. 
Then, sections were rinsed in distilled water and fixed for 10min in 10% formaldehyde. 
After post-fixation the sections were rinsed twice with distilled water, dehydrated in 
graded alcohol and mounted in Eukitt medium. To verify the staining specificity, controls 
without the substrate or at basic pH were done in parallel. No staining was detected in 
any of these controls. 
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Results 
We first characterized the brain lesion obtained using a model of focal cerebral ischemia 
adapted from Renolleau et al. (1998)19 in P12 rats (see supplementary results). The 
resulting lesion was restricted to the ipsilateral cortex and reached its maximum volume 
at 24h post-ischemia (see suppl. Fig S1).  
Then, in order to develop a relevant neuroprotective approach, we analyzed the 
different cell death mechanisms involved in the ischemic brain damage. 
 
Early necrosis at the center of the lesion 
Evidence for necrosis was demonstrated by electron microscopy and by Western blot for 
calpain-dependent fodrin cleavage, previously used as a marker of necrosis following 
cerebral ischemia24 (see Suppl. Fig S2). In this model, necrosis occurred rapidly and 
was mainly located at the center of the lesion (see Supplementary Results). 
 
Evidence for apoptotic mechanisms 
Electron microscopy revealed dying neurons with some apoptotic features in the border 
of the lesion. These neurons did not display classical criteria of apoptosis but did 
present chromatin condensation (although more irregular and fragmented than in 
classical apoptosis), cytoplasm shrinkage, and relatively good preservation of 
cytoplasmic organelles (slightly swollen) such as mitochondria in the border of the lesion 
(Fig 1A).  
We then assessed the occurrence of caspase-dependent and apoptosis-inducing 
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factor (AIF)-dependent apoptotic mechanisms. Western blot using a specific antibody 
against cleaved (activated) caspase-3 showed no detectable cleavage in the control 
condition, but a significant increase in cleavage from 6h post-reperfusion that increased 
progressively to reach its maximum value at 24h (Fig 1B). Caspase-3 dependent fodrin 
breakdown (Fig 1C) was likewise significantly increased from 6h (189% ± 21) to 24h 
(469% ± 84) (Suppl. Fig S2). By immunocytochemistry, we investigated the expression 
and cellular distribution of active caspase-3 and -9 at 24h post-reperfusion using 
antibodies that recognized only their activated forms. Cleaved caspase-3 (Fig 1C, 
arrows) and -9 (Fig 1F, arrows) were both detected mainly in the border of the lesion. 
Double labeling using both neuronal and glial markers demonstrated that cleaved 
caspase-3 (Fig 1D, E) and -9 (Fig 1G, H) were mainly colocalized with the neuronal 
marker NeuN (Fig 1D, G, arrowheads) and that no colocalizations were detected with 
the glial marker GFAP (Fig 1E, H).  
We then investigated whether the caspase-independent component of apoptosis 
was implicated, focusing on AIF (apoptosis-inducing factor), which is released from the 
mitochondria and translocated to the nucleus, where it is involved in DNA fragmentation. 
Immunocytochemistry showed a cytosolic distribution of AIF in control conditions (Fig 1I) 
but a nuclear localization in the ischemic area after cerebral ischemia (Fig 1J), 
suggesting the involvement of AIF-mediated caspase-independent apoptotic 
mechanisms. 
 
Attempts at neuroprotection using caspase inhibitors 
As apoptotic mechanisms appear to be strongly involved in our model, we investigated 
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the effects of two broad-band caspase inhibitors, Z-VAD-fmk and Q-VD-OPH (Fig 1K-N). 
We first verified that Z-VAD-fmk and Q-VD-OPH both strongly inhibited caspase-3 
activation (Figs 1K and 1M, respectively). Then, we evaluated the effect of both 
inhibitors on the infarct volume. Different doses of Z-VAD-fmk were administered icv at 
the moment of reperfusion (Fig 1L), but none of them significantly reduced the infarct 
volume as compared to the saline-treated group. Similarly, two modes of injection of 
QVD-OPH were tested (Fig 1N), but neither icv nor ip injections (at the moment of 
reperfusion) significantly reduced the lesion volume as compared to saline injected rats.  
 
Involvement of autophagy after neonatal cerebral ischemia in P12 rats 
In view of the lack of neuroprotection using caspase inhibitors, we investigated whether 
autophagic cell death mechanisms were contributing to ischemic brain damage.  
Increase in autophagosomes. To evaluate the involvement of autophagosomes, 
we used electron microscopy, Western blots and immunocytochemistry. Western blot 
analyses were performed using an antibody against LC3 (microtubule-associated 
protein 1A light chain 3). LC3 is distributed in the cytoplasm in normal conditions (LC3-I), 
but when autophagy is induced, LC3 is modified post-translationally to become LC3-II, 
which integrates the autophagosome membrane. Quantification of LC3-II was done to 
determine the level of autophagosomes in the ischemic cortex from 0h to 24h after the 
moment of reperfusion. LC3-II levels increased about 2.5-fold between 2h and 6h post-
ischemia, followed by a moderate further increase up to 24h (Fig 2A).  
Immunocytochemistry using an anti-LC3 antibody revealed at 24h the presence 
of numerous cells showing a strong LC3-positive staining (Fig 2D). At higher 
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magnification (Fig 2E), the labeling in these highly reactive neurons displayed numerous 
positive dots, presumably autophagosomes, which was quite unlike the diffuse staining 
seen in LC3-positive cells in control animals (Fig 2B, C). Double labeling experiments 
revealed that LC3 is expressed selectively in neurons, as shown by numerous 
colocalizations with NeuN (Fig 2F) in contrast to the absence of colocalization with glial 
fibrillary acidic protein (GFAP) (Fig 2G) or other glial markers such as S100β (not 
shown). At 24h (Fig 2H), electron microscopy revealed in the border of the lesion 
neurons containing numerous autophagosome-like structures filled with amorphous 
material (arrows) and autolysosomes filled with membranous whorls (arrowheads).  
 
Studies on the lysosomal pathway 
To clarify whether the increase in autophagosomes reflected an increase in autophagic 
activity (or flux) or a decrease in their turnover, we also investigated the activity of the 
lysosomal pathway. First, we performed immunocytochemistry against the lysosomal 
protease cathepsin D, and the lysosomal-associated membrane protein 1 (LAMP1), to 
investigate lysosomal expression and to characterize their cellular distribution (Fig 3). 
Already at 6h after reperfusion, an increase in the number of cathepsin D-positive dots 
was observed in cells located mainly in the border in the lesion (Fig 3B, B’). At 24h, a 
further increase in the intensity and size of the cathepsin D labeling was detected as 
compared to 6h (Fig 3C, C’). At 24h, double labeling using NeuN for neurons and 
several glial markers demonstrated that numerous cells strongly immunoreactive for 
cathepsin D are neurons (Fig 3D-D’, white arrows) whereas no colocalizations were 
obtained between cathepsin D and glial markers such as GFAP (Fig 3E, E’) and S100β 
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(not shown). 
LAMP1 immunostaining likewise increased strongly in the ischemic hemisphere 
from 6h (Fig 3G, G’) to 24h (Fig 3H, H’) post-reperfusion as compared to control cortex 
(Fig 3F, F’). At 24h, double labeling with microtubule-associated protein 2 (MAP2) 
revealed that the cells displaying intense LAMP1 labeling are neurons (Fig 4I’’) and not 
glial cells (Fig 5J’’). 
Histochemistry directed against two lysosomal hydrolases, acid phosphatase and 
β-N-acetylhexosaminidase, showed a strong increase in lysosomal activity from 6h. As 
shown in figure 4, acid phosphatase staining is enhanced (number and size of acid 
phosphatase positive dots) in neurons mainly in the border of the lesion from 6h (Fig 4B, 
B’) to 24h (Fig 4C, C’) compared to control cortex (Fig 4A, A’). The dots presumably 
show lysosomes, and the larger dots autolysosomes13. 
β-N-acetylhexosaminidase staining is likewise strongly increased in neurons 
located in the border of the ischemic area from 6h (Fig 4E, E’) to 24h (Fig 4F, F’) post-
ischemia compared to the control cortex (Fig 4D, D’). Again, both the number and the 
size of the reactive regions, presumably lysosomal, is increased. 
 
Relationship between lysosomal and autophagosomal pathways  
Double labeling at 24h post-reperfusion showed that the strong punctate 
autophagosomal labeling (LC3) and the strong lysosomal labeling (cathepsin D and 
LAMP1) are in the same neurons (Fig 4). Numerous colocalizations can be seen 
between LC3 and cathepsin D (Fig 4G’’), or between LC3 and LAMP1 (Fig 4H’’).  
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Relationship between autophagic and apoptotic mechanisms  
Double labeling was performed to investigate the relationship between autophagic and 
apoptotic mechanisms (see supplementary Fig S3). Neurons positive for cleaved 
caspase-3 (Fig S3A, D) were never strongly labeled for LAMP1 (Fig S3A’’) or cathepsin 
D (Fig S3D’’) and tended not to occur in the same region as the LAMP1 (Fig S3B’) or 
cathepsin D (Fig S3C’) positive neurons. The same approach revealed no 
colocalizations between cleaved caspase-9 and LAMP1 (Fig S3E’’, F’’) or cathepsin D 
(Fig S3G’’, H’’). 
 
Neuroprotective effect of 3-methyladenine against neonatal cerebral ischemia 
We used 3-methyladenine (3-MA), a pharmacological inhibitor of autophagy, to 
investigate the functional significance of the increase in autophagy (Fig 5). First, we 
evaluated the capacity of 3-MA to down-regulate the ischemia-induced increase in LC3-
II. Western blot analyses of ischemic extracts collected 24h after icv injections of 3-MA 
showed a strong and highly significant (p<0.01) decrease in LC3-II levels compared to 
saline-treated animals (Fig 5A). Then, we examined whether the autophagy inhibitor 
could provide neuroprotection in our ischemic model. Four groups of P12 rats received 
an icv injection of either saline or of 3-MA (60µg) at different time points after the 
beginning of reperfusion (Fig 5B). When given at the moment of reperfusion, 3-MA 
provided more than 37% of neuroprotection (Fig 5C) in terms of lesion volume evaluated 
by measurement of pale cresyl violet staining, and compared to ischemic rats injected 
with saline (Fig 5D). In view of this strong neuroprotective effect, we investigated the 
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post-ischemic therapeutic window of 3-MA by testing later icv injections of 3-MA. Even 
stronger neuroprotection (>46%) was obtained with 3-MA given at 3h but not at 6h after 
reperfusion. We also evaluated the neuroprotective effect of 3-MA along the antero-
posterior axis, and found that 3-MA treatment at 0h (Fig 5E) or at 3h (Fig 5F) was in 
both cases more neuroprotective in the more caudal part of the cortex, corresponding 
mainly to the region where delayed cell death was most prominent (level of the 
hippocampus, see supplementary Fig S1).  
 
Relationship between 3-MA treatment and nonautophagic cell death mechanisms  
We investigated the effect of blocking autophagy on nonautophagic modes of cell death 
(Fig 6). Western blots of 3-MA-treated ischemic cortex showed that 3-MA caused a 
strong and significant decrease in cleaved caspase-3 levels. As shown in Fig 8A, 3-MA 
treatment significantly reduced, by 70.6%, the activation of cleaved caspase-3 as 
compared to saline controls. 3-MA also decreased significantly, by 54.9%, the caspase-
specific fodrin cleavage product as compared to saline controls (Fig 6B). However, 3-MA 
treatment did not significantly reduce the calpain-specific fodrin cleavage product (Fig 
6B). 
 We also counted the caspase-9-positive cells in sections through the ischemic 
cortex of rats treated with 3-MA or saline (Fig 6C). In rats treated with 3-MA there was a 
strong reduction (by 72%) in the density of caspase-9 positive cells with respect to the 
saline-treated rats.  
 We then investigated the effect of 3-MA on AIF translocation to the nucleus (Fig 
6D). Counts of positive AIF nuclei at 24h of reperfusion revealed a 60.1% reduction as 
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compared to the saline control, indicating that 3-MA strongly decreased the ischemia-
induced translocation of AIF. 
 
Discussion 
 
We here report that neonatal cerebral ischemia caused early neuronal death occurring 
by necrosis in the centre of the lesion, followed by delayed neuronal death involving 
apoptotic and autophagic mechanisms at the border of the lesion. Post-ischemic 
autophagy inhibition was strongly neuroprotective whereas caspase inhibition was not. 
 
Necrosis and apoptosis 
As expected from previous studies on both adults and neonates14, 19, 24-28, cerebral 
ischemia in P12 rats induced both necrotic and apoptotic-like neuronal death. Necrosis 
occurred early after the ischemic insult and was restricted to the center of the lesion as 
deduced from both ultrastructure and the activation of calpain, a mediator of necrotic cell 
death24. Apoptotic-like cell death occurred later and was restricted to the border of the 
lesion. Neonatal cerebral ischemia strongly activated caspases-3 and -9 in neurons in 
the penumbra, as reported in other neonatal and adult models3, 28-29 and also induced 
AIF nuclear translocation, shown to occur after neonatal hypoxia-ischemia29-31, 
demonstrating that both caspase-dependent and -independent components of apoptosis 
are involved in delayed neuronal death in the present model. 
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Post-ischemic inhibition of caspase activation is not neuroprotective 
In view of the inhomogeneous potency profiles of so called “pan-caspase” inhibitors32, 
we tested both Z-VAD-fmk (the most widely used pan-caspase inhibitor) and Q-VD-OPh 
(more potent than Z-VAD-fmk, especially for caspases-2 and -6), but neither reduced 
the lesion volume at the doses used (icv and ip), despite the fact that cerebral levels of 
cleaved-caspases were strongly reduced by both inhibitors. The reason for this is not 
known. Previous studies with pan-caspase inhibitors have shown protection in various 
models ranging from neonatal cerebral hypoxia-ischemia2, 29, 31 and focal cerebral 
ischemia5 to adult focal cerebral ischemia. However, there are also reports of a lack of 
protection in these same models (e.g. neonatal cerebral hypoxia-ischemia3 and focal 
cerebral ischemia4). Various factors may have contributed to the discrepancies including 
the sex of the animals5, 30-31, the time of caspases inhibitor administration, the severity of 
the ischemic insult and the differences between the models used. The present data 
suggest that the resistance to treatment may be due to the activation of multiple cell 
death pathways, with the result that inhibiting caspases alone may be insufficient for 
protection. For this reason we hypothesized that it would be necessary to target 
additional death pathways such as the autophagic pathway. 
 
Neonatal focal cerebral ischemia-induced autophagy  
Autophagic activity is enhanced in dying neurons in hippocampal organotypic slices 
exposed to an excitotoxic dose of NMDA13, in hippocampal neurons following kainate 
injections12, 33 and in motor neurons in a model of slow glutamate excitotoxicity in vitro34. 
Recently, several studies mentioned the involvement of autophagy following cerebral 
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ischemia in both adult and neonatal models15-17, 24, 30, 35-36. Some of them indicated that 
autophagy could be implicated in mediating cell death17, 36 but more investigations are 
needed to clarify this. 
To demonstrate that autophagic mechanisms are increased it is not sufficient to 
show an increase in the number of autophagosomes or an increased expression of LC3-
II, because these changes could be caused merely by a slower elimination of 
autophagosomes due to a reduction in lysosomal activity or a defect in autophagosome-
lysosome fusion. Previous studies on other models of cerebral ischemia showed 
increases in autophagosomal markers29, 16-17, 36 or in lysosomal protease activities37-39. 
We here demonstrated that the increases occurred in both autophagosomal and 
lysosomal markers and that both occurred in the same stressed neurons, providing 
unequivocal evidence that the autophagosomal increases were not due to a reduction in 
lysosomal activity. The alternative possibility of a defect in autophagosome-lysosome 
fusion can also be rejected because our ultrastructural observations showed that 
autolysosomes (created by autophagosome-lysosome fusion) were far more abundant 
in the ischemic area than in control tissue. Hence one can conclude that autophagic 
activity (i.e. flux) was indeed increased. In view of the autophagic neurons’ location in 
the border of the lesion, the enhanced autophagy could be implicated in mediating the 
delayed neuronal death. 
 
Post-ischemic autophagy inhibition promotes strong neuroprotection 
Very recent studies have suggested that autophagy could be implicated in neuronal 
death following cerebral ischemia. Wen et al.36 reported that 3-MA could promote 
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moderate neuroprotection in adult focal cerebral ischemia. Koike et al.17 described 
strongly enhanced autophagy following hypoxia-ischemia in both neonatal and adult 
mice, and showed that deletion of Atg7 protected hippocampal pyramidal neurons in the 
neonates. Nevertheless, to date no study has reported neuroprotection due to post-
ischemic inhibition of autophagy. 
Having provided evidence that ischemia triggers an enhanced autophagic flux, 
we tested the effects of inhibiting autophagy with 3-MA. Despite its potential 
proapoptotic side effects due to inhibition of the anti-apoptotic phosphatidylinositol 3-
phosphate kinase/Akt pathway, 3-MA treatment was strongly neuroprotective, reducing 
the lesion volume by 37%. Furthermore, 3-MA was strongly protective (by 46%) even 
when given 3h after the end of the ischemic insult (i.e more than 4h after the beginning 
of the ischemia). Taken together, these results indicate that delayed neuronal death 
mechanisms may be mediated by enhanced autophagy, suggesting a therapeutic 
potential of autophagy inhibition in neonatal stroke.  
 
Energy-dependence of cell death 
It is widely accepted that apoptosis and autophagy are energy-dependent and that 
energy failure causes necrosis, although it is not clear whether the necrotic nature of this 
cell death is due solely to the failure of apoptosis and autophagy, or whether it is due 
also to other factors such as the faster demolition rate by necrotic mechanisms following 
massive calcium influx in energy-deprived cells. In focal cerebral ischemia it is generally 
accepted that apoptosis tends to occur late and at the border of the ischemic area, 
whereas necrosis occurs earlier and at the centre40, 41. Since autophagy is energy-
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dependent, one would expect autophagy-expressing cell death to occur likewise in the 
border region; as had previously been reported in an ultrastructural study of transient 
focal ischemia in adults42, and our present results provide strong confirmation. There is 
also evidence for a continuum of neuronal death morphology in which gradual 
transitions from necrotic to necrotic-apoptotic to apoptotic morphologies occur along a 
temporal or spatial gradient, and this has been attributed to a corresponding energy 
gradient25, 43-46. The question arises therefore whether autophagy-expressing neuronal 
death can fit into such a scheme, and the above-cited work of Aggoun-Zouaoui42 does 
provide some support for a gradient from necrosis at the lesion centre to apoptosis at its 
extreme border with autophagy-expressing neuronal death between the two.  
 
Relationship between autophagic and apoptotic mechanisms 
To clarify whether the effects of 3-MA involved interactions with nonautophagic 
pathways, we investigated its effect on necrotic (calpain) and apoptotic (caspases and 
AIF) markers. It had no effect on calpain activation, but decreased caspase activation 
and AIF nuclear translocation, indicating that it inhibited both the caspase-dependent 
and -independent apoptotic pathways. Apoptosis and autophagy are morphologically 
different types of programmed cell death, and can function independently, but numerous 
interactions between these two pathways have been described, and modifications of the 
autophagic pathway can influence apoptosis7-8, 47-48. Indeed calpain-mediated cleavage 
of Atg5 was demonstrated to mediate a switch from autophagy to apoptosis48. Excessive 
autophagy (by overexpression of Atg1) can induce apoptotic cell death49 and several 
reports concerning neurons mentioned the involvement of autophagy before apoptosis 
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following an apoptotic stimulus such as nerve growth factor deprivation in sympathetic 
neurons50, chloriquine treatment in cortical neurons51, or low-potassium induced 
apoptosis in cultured cerebellar granule cells11. Other studies have demonstrated that 
both autophagy and apoptosis can occur within the same cells. Indeed Rami et al.16 
showed colocalizations between caspase-3 and increased beclin-1 expression following 
focal cerebral ischemia in adult rats. Another recent study also showed that 3-MA was 
able to reverse the apoptotic death of rat striatal neurons induced by kainic acid33. In the 
work of Koike et al.17, the apoptotic pathway (caspase-3 activation and DNA 
fragmentation) was inhibited by Atg7 deficiency in the hippocampus after neonatal HI. 
Thus, autophagy can contribute to programmed cell death by activating the apoptotic 
pathway. 
Nevertheless, in our study activated caspase-3/9 never colocalized with the 
strong LAMP1 or cathepsin D immunolabelling, suggesting that the apoptotic and 
autophagic processes occurred in different neurons or at different times in the same 
neurons. We obtained a similar lack of colocalization in double-labeling experiments for 
LC3 and TUNEL (data not shown). Interestingly neurons displaying either strong 
autophagic features or caspase activation were located in the border of the lesion where 
delayed cell death occurs. While it is true that 3-MA reduced caspase-3 activation, this 
was probably not the main cause of the protection, because pan-caspase inhibitors did 
not provide any neuroprotective effect. In a study on chloriquine-induced neuronal 
death, which displayed autophagic features, 3-MA was protective whereas pan-caspase 
inhibitors were not51.  
We therefore hypothesize that autophagy may mediate neuronal death in our 
neonatal stroke model by acting in two different ways: by triggering apoptosis (via 
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caspase-mediated and AIF-mediated pathways), and independently of apoptosis by a 
pure autophagic death pathway. The relevance of this to other models such as the 
neonatal hypoxia-ischemia model of cerebral asphyxia remains to be determined and 
will be the subject of another study.  
 
Conclusion  
In conclusion, we here provide evidence for a major involvement of autophagy in 
mediating neuronal death following focal cerebral ischemia in neonatal rats. We also 
report for the first time the neuroprotective effects of an autophagy inhibitor administered 
after the insult, opening new therapeutic possibilities. 
 
Acknowledgments 
We thank Sonia Naegele-Tollardo, Vanessa Waechter, Coralie Rummel and Kirsi 
Bourget for technical assistance, Jean-Yves Chatton and Yannick Krempp of the 
Cellular Imaging Facility (University of Lausanne) for experimental support, and the 
Centre of Electron Microscopy at the University of Lausanne for the use of their electron 
microscopes. This research was supported by grants from the Swiss National Science 
Foundation (3100A0-101696 and -113925) and from the Fondation Motrice.  
 
 
 
Supplementary information is available at Annals of Neurology’s website. 
 
 24 
 References 
 
1. Ferriero DM. Neonatal brain injury. N Engl J Med 2004;351:1985-95. 
2. Cheng Y, Deshmukh M, D'Costa A et al. Caspase inhibitor affords neuroprotection 
with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. 
J Clin Invest 1998;101:1992-9. 
3. Gill R, Soriano M, Blomgren K et al. Role of caspase-3 activation in cerebral 
ischemia-induced neurodegeneration in adult and neonatal brain. J Cereb Blood 
Flow Metab. 2002;22:420-30. 
4. Joly LM, Mucignat V, Mariani J et al. Caspase inhibition after neonatal ischemia in the 
rat brain. J Cereb Blood Flow Metab 2004;24:124-31. 
5. Renolleau S, Fau S, Goyenvalle C et al. Specific caspase inhibitor Q-VD-OPh 
prevents neonatal stroke in P7 rat: a role for gender. J Neurochem 2007;100:1062-
71. 
6. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. 
Science 2004;306:990-5. 
7. Shimizu S, Kanaseki T, Mizushima N et al. Role of Bcl-2 family proteins in a non-
apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 
2004;6:1221-8. 
8. Yu L, Alva A, Su H et al. Regulation of an ATG7-beclin 1 program of autophagic cell 
death by caspase-8. Science 2004;304:1500-2. 
9. Nixon RA. Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends 
Neurosci 2006;29:528-35. 
 25 
10. Clarke PGH. Developmental cell death: morphological diversity and multiple 
mechanisms. Anat Embryol (Berl) 1990;181:195-213. 
11. Canu N, Tufi R, Serafino AL et al. Role of the autophagic-lysosomal system on low 
potassium-induced apoptosis in cultured cerebellar granule cells. J Neurochem 
2005;92:1228-42. 
12. Shacka JJ, Lu J, Xie ZL et al. Kainic acid induces early and transient autophagic 
stress in mouse hippocampus. Neurosci Lett 2007;414:57-60. 
13. Borsello T, Croquelois K, Hornung JP, Clarke PGH. N-methyl-d-aspartate-triggered 
neuronal death in organotypic hippocampal cultures is endocytic, autophagic and 
mediated by the c-Jun N-terminal kinase pathway. Eur J Neurosci 2003;18:473-85. 
14. Nitatori T, Sato N, Waguri S et al. Delayed neuronal death in the CA1 pyramidal cell 
layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci 
1995;15:1001-11. 
15. Adhami F, Liao G, Morozov YM et al. Cerebral ischemia-hypoxia induces 
intravascular coagulation and autophagy. Am J Pathol 2006;169:566-83. 
16. Rami A, Langhagen A, Steiger S. Focal cerebral ischemia induces upregulation of 
Beclin 1 and autophagy-like cell death. Neurobiol Dis 2008; 29:132-41. 
17. Koike M, Shibata M, Tadakoshi M et al. Inhibition of autophagy prevents 
hippocampal pyramidal neuron death after hypoxic-ischemic injury. Am J Pathol 
2008;172:454-69.  
18. Ashwal S, Pearce WJ. Animal models of neonatal stroke. Curr Opin Pediatr 
2001;13:506-16. 
 26 
19. Renolleau S, Aggoun-Zouaoui D, Ben-Ari Y, Charriaut-Marlangue C. A model of 
transient unilateral focal ischemia with reperfusion in the P7 neonatal rat: 
morphological changes indicative of apoptosis. Stroke 1998;29:1454-60. 
20. Puyal J, Vaslin A, Waechter V et al. Autophagic cell death and transient focal 
cerebral ischemia in neonatal rats. FENS Abstr 2006;3: A132.27.  
21. Puyal J, Vaslin A, Bourget K et al. Autophagy mediates neuronal death in neonatal 
cerebral ischemia: a new target for neuroprotection? 2007;8e Colloque de la Société 
des neurosciences, A3O. 
22. Gömöri G. Distribution of acid phosphatase in tissues under normal and under 
pathologic conditions. Arch Path 1941;32:189-199. 
23. Katayama Y, Kobatake H, Shida H. A modified technique of histochemical 
demonstration for N-acetyl-β-hexosaminidase. Acta Histochem Cytochem 
1976;9:111-124. 
24. Zhu C, Wang X, Xu F et al. The influence of age on apoptotic and other mechanisms 
of cell death after cerebral hypoxia-ischemia. Cell Death Differ 2005;12:162-76. 
25. Northington FJ, Ferriero DM, Graham EM et al. Early Neurodegeneration after 
Hypoxia-Ischemia in Neonatal Rat Is Necrosis while Delayed Neuronal Death Is 
Apoptosis. Neurobiol Dis 2001;8:207-19. 
26. Liu CL, Siesjö BK, Hu BR. Pathogenesis of hippocampal neuronal death after 
hypoxia-ischemia changes during brain development. Neuroscience 2004;127:113-
25.  
27. Renolleau S, Benjelloun N, Ben-Ari Y, Charriaut-Marlangue C. Regulation of 
apoptosis-associated proteins in cell death following transient focal ischemia in rat 
pups. Apoptosis 1997;2:368-76. 
 27 
28. Benjelloun N, Joly LM, Palmier B et al. Apoptotic mitochondrial pathway in neurones 
and astrocytes after neonatal hypoxia-ischaemia in the rat brain. Neuropathol Appl 
Neurobiol 2003;29:350-60. 
29. Zhu C, Qiu L, Wang X et al. Involvement of apoptosis-inducing factor in neuronal 
death after hypoxia-ischemia in the neonatal rat brain. J Neurochem 2003;86:306-17.  
30. Zhu C, Xu F, Wang X et al. Different apoptotic mechanisms are activated in male 
and female brains after neonatal hypoxia-ischaemia. J Neurochem 2006;96:1016-27. 
31. Zhu C, Wang X, Huang Z et al. Apoptosis-inducing factor is a major contributor to 
neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ 
2007;14:775-84. 
32. Chauvier D, Ankri S, Charriaut-Marlangue C et al. Broad-spectrum caspase 
inhibitors: from myth to reality? Cell Death Differ 2007;14:387-91. 
33. Wang Y, Han R, Liang ZQ et al. An autophagic mechanism is involved in apoptotic 
death of rat striatal neurons induced by the non-N-methyl-D-aspartate receptor 
agonist kainic acid. Autophagy 2008;4;214-26. 
34. Matyja E, Taraszewska A, Nagańska E et al. Autophagic degeneration of motor 
neurons in a model of slow glutamate excitotoxicity in vitro. Ultrastruct Pathol 
2005;29:331-9. 
35. Erlich S, Shohami E, Pinkas-Kramarski R. Neurodegeneration induces upregulation 
of Beclin 1. Autophagy 2006;2:49-51. 
36. Wen YD, Sheng R, Zhang LS et al. Neuronal injury in rat model of permanent focal 
cerebral ischemia is associated with activation of autophagic and lysosomal 
pathways. Autophagy 2008;4:762-9. 
 28 
37. Uchiyama Y. Autophagic cell death and its execution by lysosomal cathepsins. Arch 
Histol Cytol 2001;64:233-46. 
38. Nitatori T, Sato N, Kominami E, Uchiyama Y. Participation of cathepsins B, H, and L 
in perikaryal condensation of CA1 pyramidal neurons undergoing apoptosis after 
brief ischemia. Adv Exp Med Biol 1996;389:177-85. 
39. Kohda Y, Yamashima T, Sakuda K et al. Dynamic changes of cathepsins B and L 
expression in the monkey hippocampus after transient ischemia. Biochem Biophys 
Res Commun 1996;228:616-22. 
40. Ferrer I. Apoptosis: future targets for neuroprotective strategies. Cerebrovasc Dis 
2006;21 Suppl 2:9-20.  
41. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. 
Neuropharmacology 2008;55:310-8. 
42. Aggoun-Zouaoui D, Margalli I, Borrega F et al. Ultrastructural morphology of 
neuronal death following reversible focal ischemia in the rat. Apoptosis 1998;3:133-
41. 
43. Portera-Cailliau C, Price DL, Martin LJ. Non-NMDA and NMDA receptor-mediated 
excitotoxic neuronal deaths in adult brain are morphologically distinct: further 
evidence for an apoptosis-necrosis continuum. J Comp Neurol 1997;378(1):88-104. 
44. Portera-Cailliau C, Price DL, Martin LJ. Excitotoxic neuronal death in the immature 
brain is an apoptosis-necrosis morphological continuum. J Comp Neurol 
1997;378(1):70-87. 
45. Northington FJ, Zelaya ME, O'Riordan DP et al. Failure to complete apoptosis 
following neonatal hypoxia-ischemia manifests as "continuum" phenotype of cell 
 29 
death and occurs with multiple manifestations of mitochondrial dysfunction in rodent 
forebrain. Neuroscience 2007;149(4):822-33. 
46. Blomgren K, Leist M, Groc L. Pathological apoptosis in the developing brain. 
Apoptosis 2007;12:993-1010. 
47. Boya P, González-Polo RA, Casares N et al. Inhibition of macroautophagy triggers 
apoptosis. Mol Cell Biol 2005;25:1025-40. 
48. Yousefi S, Perozzo R, Schmid I et al. Calpain-mediated cleavage of Atg5 switches 
autophagy to apoptosis. Nat Cell Biol 2006;8:1124-32. 
49. Scott RC, Juhász G, Neufeld TP. Direct induction of autophagy by Atg1 inhibits cell 
growth and induces apoptotic cell death. Curr Biol 2007;17:1-11. 
50. Xue  L, Fletcher GC, Tolkovsky AM. Autophagy is activated by apoptotic signalling in 
sympathetic neurons: an alternative mechanism of death execution. Mol Cell 
Neurosci 1999;14:180-98. 
51. Zaidi AU, McDonough JS, Klocke BJ et al. Chloroquine-induced neuronal cell death 
is p53 and Bcl-2 family-dependent but caspase-independent. J Neuropathol Exp 
Neurol 2001;60:937-45.  
 
 
 30 
Figure Legends 
Figure 1: Involvement of apoptosis following cerebral ischemia at P12. 
(A) Electron microscopy micrograph showing a dying neuron with some apoptotic 
features in the border of the lesion at 24h post-reperfusion. Note the chromatin 
condensation in the nucleus (n) and the cytoplasmic shrinkage (dark cytoplasm). (B) 
Representative cleaved caspase-3 immunoblot of ischemic cortex homogenates after 
0h, 2h, 6h, 12h and 24h of reperfusion. Quantification of cleaved caspase-3 in 
homogenates of ischemic cortex after 0h, 2h, 6h, 12h and 24h (n>5 per group). 
Caspase-3 activity was significantly differently from zero at 6h post-ischemia and 
increased progressively from then to reach its maximum value at 24h. The tubulin bands 
confirm equal loading. OD, optic density. Data represent mean ±SEM. Comparisons by 
t-test with control: *, p < 0.05; **, p < 0.01. (C-H) Expression and cellular distribution of 
cleaved caspase-3 and -9 in P12 ischemic cortex at 24h. Cells positive for cleaved 
caspase-3 (C) and -9 (F) are seen in the border of the lesion at 24h (arrows). By 
confocal microscopy, double labeling of cleaved caspase-3 (D) or cleaved caspase-9 
(G) (red) with NeuN (green) reveals numerous colocalizations (yellow, arrowheads) 
whereas double labeling of cleaved caspase-3 (E) or -9 (H) (red) and GFAP (green) 
shows none. (I-J) Expression and cellular distribution of AIF in both control (I) and 
ischemic cortex at 24h (J). Note that AIF is abundant in the nucleus following cerebral 
ischemia, unlike in the control. (K-N) Attempts at neuroprotection using the caspase 
inhibitors Z-VAD-fmk and Q-VD-OPH. (K) Quantification of cleaved caspase-3 in 
ischemic cortex homogenates of rats treated with saline or 500ng Z-VAD-fmk icv 
measured at 24h of reperfusion (n>5 per group). Z-VAD-fmk treatment strongly reduced 
the caspase-3 cleavage by 71.56% ± 9.08. (L) Lack of effect of post-ischemic Z-VAD-
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fmk administration (80, 160 or 500 ng icv) on brain injury at 24h. In no case did Z-VAD-
fmk give neuroprotection (58.3±11.7, n=8, 59.7±9.4, n=5 and 60.8±11.0mm3, n=5 for 80, 
160 and 500ng-doses respectively) compared to saline (61±8.2mm3, n=15). ANOVA 
showed no significant differences between the groups (p = 0.9974). (M) Quantification of 
cleaved caspase-3 in ischemic cortex homogenates from rats treated with saline, 1.3µg 
Q-VD-OPH icv, or 1mg/kg Q-VD-OPH ip at 24h of reperfusion (n>5 per group). Q-VD-
OPH treatment strongly reduced the caspase-3 cleavage by 81.23% ± 3.05 (1.3µg, icv) 
or by 87.38% ± 6.36 (1mg/kg, ip). (N) Lack of effect of post-ischemic administration of Q-
VD-OPH on brain injury in the same groups of rats as used for quantification of caspase 
cleavage. Q-VD-OPH injections did not provide significant neuroprotection, whether 
given icv (67.2±5.7mm3, n=6) or ip (65.7±5.8mm3, n=6) compared to saline 
(73.6±6.9mm3, n=6). ANOVA showed no significant differences between the groups (p = 
0.638). Bars: A = 5µm; C, F = 250µm; D, E, G, H = 100µm; I, J = 50µm. 
 
 Figure 2: Increase in autophagosomes after neonatal cerebral ischemia at P12.  
(A) Upper panel: representative immunoblot of LC3 in extracts of ischemic cortex at 0h, 
2h, 6h, 12h and 24h after reperfusion. Lower panel: quantification of the LC3-II band 
intensity expressed as a percentage of control LC3-II (n>5 per group), At 6h, the level of 
LC3-II in ischemic cortex had already reached 257% ± 32 of the control level, and at 24h 
was at 315% ± 27 of the control. Tubulin staining confirms equal loading. Data represent 
mean ±SEM. Comparisons by t-test with control: *, p < 0.05; **, p < 0.01. (B-G) 
Expression and distribution of LC3 after neonatal cerebral ischemia in P12 rats. 
Immunocytochemistry showed that LC3 labeling increased and appeared as numerous 
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positive dots in the cytoplasm of cells in the ischemic area (D, E), whereas non-ischemic 
brains displayed a less intense and more diffuse staining (B, C). Double labeling for LC3 
(red) and NeuN (green) of sections from the ischemic area demonstrated that LC3 is 
restricted to neuronal compartments (F, yellow), whereas double labeling for LC3 (red) 
and GFAP (green) showed no colocalization (G). (H) Electron micrograph in the border 
of the lesion at 24h showing a neuron with numerous autophagosome-like structures 
(arrows) and autolysosomes containing membranous whorls (arrowheads). Bars: B, D = 
50µm; C, E = 25µm; F, G = 50µm; H = 2µm.  
 
Figure 3: Immunocytochemistry for cathepsin D (left) and LAMP1 (right) after 
cerebral ischemia in P12 rats.  
Cathepsin D immunolabeling increased following cerebral ischemia from 6h (B, B’) to 
24h (C, C’) as compared to control rat (unoperated) (A, A’). At high magnification (B’-
C’), this enhancement is seen to reflect an increase in the number and size of cathepsin 
D positive cytosolic particles (presumably autolysosomes). Confocal microscopy of 
sections double labeled for cathepsin D (red) and NeuN (green) showed numerous 
colocalizations (D, D’, white arrows) whereas double labeling for cathepsin D (red) and 
GFAP (green) showed none (E, E’). LAMP1 immunocytochemistry showed enhanced 
LAMP1 staining from 6h (G, G’) to 24h (H, H’) post-ischemia as compared to control rat 
(F, F’). Double labeling and confocal microscopy for LAMP1 (I, red) and NeuN (I’, green) 
shows that increased LAMP1 expression is in NeuN positive cells (I’’) whereas double 
labeling for LAMP1 (J, red) and GFAP (J’, green) shows no colocalization (J’’). Bars: A-
E, F-H, I-I’’, J-J’’ = 25µm; A’-C’, F’-H’ = 5µm; D’-E’ = 10µm.  
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Figure 4: Acid phosphatase and β-hexosaminidase histochemistry and 
relationship between lysosomal and autophagosomal pathways after cerebral 
ischemia in P12 rats. 
A strong increase in acid phosphatase staining is observed from 6h (B) to 24h post-
reperfusion (C) in the ischemic area as compared to the control cortex (A). At higher 
magnification, this enhancement is seen to involve an increase in the number of acid 
phosphatase positive dots at 6h (B’) and in both their number and size at 24h (C’) 
compared to control (A’). β-hexosaminidase histochemistry revealed a similar increase 
in staining from 6h (E, E’) to 24h (F, F’) post-ischemia as compared to control cortex (D, 
D’). At 24h, double labeling and confocal microscopy using cathepsin D and LC3 
antibodies showed that the increase in cathepsin D (G, green) and LC3 (G’, red) 
occurred in the same neurons as demonstrated by numerous colocalizations (G’’, 
yellow). Double labeling with LAMP1 (H, green) and LC3 (H’, red) also displayed 
numerous colocalizations (H’’, yellow). Bars: A-C, D-F; G-G’’: 50µm; H-H’’: 25µm; A’-C’, 
D’-F’: 10µm.  
 
Figure 5: Protective effect of 3-methyladenine treatment following cerebral 
ischemia at P12.  
(A) Reduction of autophagy shown by Western blots for LC3-II. Saline (0.9% NaCl) or 3-
methyladenine (3-MA) (60µg) solutions were injected icv at the time of reperfusion. 
Upper panel: representative immunoblot showing the effect of 3-MA on the autophagy 
marker LC3-II in extracts of ischemic cortex at 24h post-reperfusion. Lower panel: 
densitometric quantification of immunoreactive band intensities expressed as a 
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percentage of control LC3-II (n>5 per group). 3-MA treatment almost completely inhibits 
the ischemia-dependent increase in LC3-II. Tubulin staining confirms equal loading. IL, 
ipsilateral; CL, contralateral; S, Saline. Data represent mean ±SEM. Comparisons by t-
test with saline: *, p < 0.05; **, p < 0.01. (B) Effect of post-ischemic 3-MA administration 
on lesion volume at 24h. A single icv injection of 3-MA (60 µg) was performed at 
different times after reperfusion: 0h (n=9), 3h (n=7), 6h (n=6) compared to saline 
injected animals (n=9). 3-MA induced a substantial and significant reduction of the 
infarct volume when injected at 0h (34.6±6.0mm3; p=0.009) or 3h (29.2±5.3mm3; 
p=0.0015) post-ischemia as compared to saline (55.1±4.8mm3), but not when injection 
occurred 6h after ischemia (53.4±8.2mm3). Data represent mean ±SEM. Comparisons 
by t-test with saline: *, p < 0.05; **, p < 0.01. (C-D) Cresyl violet-stained sections 
showing representative brain injuries after icv injections of saline (C) or 3-MA 0h (D) at 
the level of the striatum and the hippocampus after 24h of reperfusion. Bar = 1mm. (E, 
F) Evaluation of the neuroprotective role of 3-MA in relation to the anterior to posterior 
distance. The neuroprotection was strongest at the level of the hippocampus, whether 3-
MA was injected at 0h (E) or 3h (F) after reperfusion. Data represent mean ±SEM. 
Comparisons by t-test with saline: *, p < 0.05; **, p < 0.01.  
 
Figure 6: Effect of 3-methyladenine treatment on nonautophagic modes of cell 
death after cerebral ischemia at P12.  
Saline (0.9% NaCl) or 3-methyladenine (3-MA) (60µg) solutions were injected icv at the 
time of reperfusion. (A) Effect of 3-MA treatment on caspase-3 activation. Upper panel: 
Representative immunoblot of cleaved caspase 3 in extracts of ischemic cortex at 24h of 
reperfusion from rats treated with 3-MA or saline. Lower panel: Quantification of cleaved 
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caspase 3 in the 3-MA-treated and saline-treated rats (n>5 per group). IL, ipsilateral; CL, 
contralateral. (B) Effect of 3-MA treatment on calpain activation. Upper panel: 
Representative immunoblot showing the calpain- and caspase-dependent fodrin 
cleavage products in extracts of ischemic cortex at 24h of reperfusion from rats treated 
with 3-MA or saline. IL, ipsilateral; CL, contralateral. Middle panel: Quantification of 
calpain-specific fodrin cleaved product (150 kDa) in the 3-MA and saline groups (n>5 
per group). Lower panel: Quantification of caspase-specific fodrin cleaved product (120 
kDa) in the 3-MA and saline groups (n>5 per group). Tubulin staining confirmed equal 
loading. Comparisons by t-test with saline: *, p < 0.05; **, p < 0.01. (C) Numbers of cells 
positive for cleaved caspase-9 per mm2 in ischemic cortex at 24 h from rats treated with 
3-MA (109.7 ± 19.4/mm2) or saline (480.6 ± 36.9/mm2). Data represent mean ±SEM. 
Comparisons by t-test with saline: *, p < 0.05; **, p < 0.01. (D) Numbers of AIF positive 
nuclei per mm2 in ischemic cortex at 24 h from rats treated with 3-MA (107.8±17.7/mm2) 
or saline. Data represent mean ±SEM. Comparisons by t-test with saline 
(270±31.3/mm2). *, p < 0.05; **, p < 0.01. 
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Supplementary Materials and Methods 
 
Light microscopic immunocytochemistry  
The rats were deeply anesthetized with pentobarbital (6mg/100mg body weight, 
Ip) and transcardially perfused (n >10 for each time) with 4% paraformaldehyde 
in 0.1M PBS, pH 7.4. The brain was rapidly dissected-out and post-fixed 
overnight at 4°C in the same fixative. Immunocytochemistry was carried out on 
both cryostat and vibratome coronal sections of the brain. For cryostat sections, 
the samples were immersed overnight in 30% sucrose in PBS at 4°C and frozen 
sections (18 µm) were collected on polylysine-coated slides. For vibratome 
sections, brains were washed thoroughly for 3h in PBS. Then 30-50 µm thick 
sections were cut on a Vibratome and collected serially in cold 0.1M PBS. 
For fluorescence and confocal microscopy, sections were pre-incubated in 
PBS supplemented with 15% donkey serum and 0.3% Triton X-100 for 45 
minutes at RT, and then incubated overnight at room temperature with the 
primary antibodies. All antibodies were diluted in PBS supplemented with 1.5% 
donkey serum and 0.1% Triton X-100. The antibodies used were as follows: anti-
MAP2 rabbit antibody (#AB5622, Millipore, Temacula, CA, USA), anti-NeuN 
mouse (#MAB377, Millipore, Temacula, CA, USA), anti-GFAP mouse (#G3893, 
Sigma, St. Louis, MO, USA), anti-S100β mouse (#S2532, Sigma, St. Louis, MO, 
USA), anti-LAMP1 mouse (#428017, Calbiochem, La Jolla, CA, USA) , anti-
Cathepsin D rabbit (#06-467, Upstate, Charlottesville, VA, USA ), anti-Cathepsin 
D goat (#sc-6486, Santa-Cruz Biotechnology, CA, USA), anti-LC3 rabbit 
(generous gift from Pr. Uchiyama), anti-AIF rabbit (#sc-5586, Santa-Cruz 
Biotechnology, CA, USA), anti-caspase 3 rabbit (#9661, Cell Signaling 
Technologies, Danvers, MA, USA), anti-caspase 9 rabbit (#9507, Cell Signaling 
Technologies, Danvers, MA, USA).  
The sections were rinsed in PBS three times, for 10 minutes each, and 
then incubated with the secondary antibodies for 1 hour and 30 minutes: Alexa 
Fluor 594-labeled donkey IgGs or Alexa Fluor 488–labeled donkey anti-rabbit, 
anti-mouse or anti-goat IgGs (Molecular Probes, Eugene, OR, USA) depending 
on the first antibody. The sections were thoroughly rinsed in PBS and mounted in 
FluorSave (Calbiochem, San Diego, CA, USA). The sections were double-
labeled, as above, by incubation with mixtures of poly- and monoclonal 
antibodies. The primary antibodies were detected with a mixture of Alexa Fluor 
647-labeled anti-rabbit IgGs and Alexa Fluor 488-labeled anti-mouse IgGs, both 
diluted 1:200 in PBS. Control sections were incubated in the absence of primary 
antibodies. No specific immunofluorescence was detected for any of these 
controls. A LSM 510 Meta confocal microscope (Carl Zeiss, Thornwood, NY, 
USA) was used for confocal laser microscopy. Confocal images are displayed as 
individual optical sections. For double-labeling, immunoreactive signals were 
sequentially visualized in the same section with two distinct filters, with 
acquisition performed in separated mode. Images were processed with LSM 510 
software and mounted using Adobe Photoshop. 
For peroxidase revelation, endogenous peroxidase activity was blocked 
with 3% H2O2 in methanol for 20min. Primary antibodies were incubated as 
previously described followed by another 2h with a biotinylated donkey anti-
mouse  or donkey anti-rabbit or donkey anti-goat  (Jackson Immunoresearch, 
West Grove, PA, USA) diluted 1:500 in PBS. Visualization was performed using 
Vectastain ABC Elite.  
 
Cell counting 
In different areas of ischemic cortex treated with saline (n≥5) or 3-MA (n≥5) at 
24h post-ischemia, cells immunopositive for caspase-9, or containing AIF-
positive nuclei, were counted at 20x magnification and expressed as an average 
number per mm2. All data were expressed as mean ± SEM. Data were analyzed 
statistically by one-way ANOVA followed by Student’s t-test (one-tailed, two-
sample, and unequal variance). Unless specifically stated, ANOVA showed 
significant differences between the groups (p< 0.05). 
 
 
Electron microscopy 
At different times after ischemia, animals were anesthetized with pentobarbital 
(6mg/100mg body weight, Ip) and perfused intracardially with fixative (2.5% 
glutaraldehyde and 2% paraformaldehyde) diluted in cacodylate buffer (0.1M, pH 
7.4). The brain was rapidly dissected-out and post-fixed overnight at 4°C in the 
same fixative. Coronal vibratome sections (200-50μm thick) were cut and rinsed 
in cacodylate buffer. Sections were then postfixed in osmium tetroxide (1% in 
cacodylate buffer) for 30 min and contrasted in uranyl acetate (1% in ethanol 
70%) for 5min. Sections were then dehydrated in graded alcohols and embedded 
in Durcarpan ACM resin (Fluka, Neu-Ulm, Germany) between silicon-coated 
glass slides. Regions of cortex were prepared and ultrathin sections (at a silver to 
gray interference) were cut with a diamond knife (Diatome). Sections were 
mounted on formvar-coated single slot grids. Sections were then contrasted with 
uranyl acetate and alkaline lead citrate. Sections were visualized using a Philips 
CM10 transmission electron microscope. 
 
Western blots 
Animals were killed by decapitation at different times after the beginning of the 
reperfusion (n>6 for each). Controls animals were killed on P13. The brains were 
rapidly dissected out in cold PBS containing 1mM MgCl2, and the ipsilateral and 
contralateral cortices collected and homogenized in cold homogenization buffer: 
Hepes pH 7.4 20mM, NaCl 10mM, MgCl2 3mM, EGTA 2.5mM, DTT 0.1mM, NaF 
50mM, Na3VO4 1mM, NP40 1% and freshly added complete EDTA-free anti-
protease cocktail (Roche, cat.n°11873580001). Homogenization was performed 
gently by hand using a 2ml glass/glass homogenizer and the homogenate was 
sonicated and used for Western blotting. 
 The protein concentration of samples was determined using a Bradford 
assay and cell extracts were boiled for 3min in sodium dodecyl sulfate (SDS) 
buffer. The same quantities of proteins for each sample were resolved by SDS-
PAGE (8%, 10% or 15% polyacrylamide) and transferred to a PVDF-membrane. 
After transfer, the membranes were blocked in 5% milk in TBS-T (Tris 200mM, 
NaCl 1.5M, Tween 20 0.1%) for 1h and incubated with the primary antibody in 
5% milk in TBS-T overnight at 4°C. Anti-LC3 (#PD012, MBL, Naka-Ku Nagoya, 
Japan) was used at 1:1000, anti-cleaved caspase 3 was at 1:1000, anti-fodrin 
(#FG6090, Biomol international, Plymouth Meeting, PA, USA) at 1:1000 and anti-
tubulin (#SC-8035, Santa-Cruz Biotechnology, CA, USA) at 1:5000. The 
membranes were washed, blocked in 1% milk in TBS-T for 30 min and incubated 
for 1h at RT with secondary horseradish peroxidase-coupled antibody (1:500, 
Pierce Biotechnology, Rockford, IL, USA) in 1% milk in TBS-T. After washes, 
immunoreactive products were detected by the enhanced chemiluminescence 
method. For reprobing, blots were stripped in SDS 2%, Tris 200mM, NaCl 1.5M 
and mercaptoethanol 100mM for 30 min at 60°C, washed with TBS and blocked 
again. The quantification of Western blots was performed using ImageQuant TL 
software (Amersham Biosciences) and values were normalized with respect to 
tubulin. The values were then expressed as a percentage relative to the control 
optical density (O.D) value. All data were expressed as mean ± SEM. Data were 
first verified to be normally distributed and then analyzed statistically by one-way 
ANOVA followed by Student’s t-test (one-tailed, two-sample, and unequal 
variance). Unless specifically stated, ANOVA showed significant differences 
between the groups (p< 0.05).  
 
 
 
Supplementary Results 
Brain lesion characterization after focal cerebral ischemia in P12 rats 
Focal cerebral ischemia was performed as previously described by Renolleau et 
al. (1998) with slight modifications. In the present study, the experiments were 
done in P12 rats and involved permanent occlusion of the middle cerebral artery 
followed by a transient (90 min) occlusion of the ipsilateral common carotid 
artery. The lesion was distinct and highly reproducible, being restricted mainly to 
the cortex but extending in some cases to the striatum. It started to be detectable 
at 5h after the beginning of the reperfusion (Suppl. Fig. S1A) and increased to 
reach its maximum value at 24h (Suppl. Fig. S1B), decreasing progressively 
thereafter to become a brain cavity as illustrated at the end of the first week 
(Suppl. Fig. S1C) and at P28 (Suppl. Fig. S1D).   
We determined the spatio-temporal pattern of lesion development by 
measuring the cortical infarct area at different levels along the antero-posterior 
axis (Paxinos, 1988) at different times after reperfusion (Figure S1F). This 
revealed that the lesion developed fastest at the level of the striatum, and then 
spread caudally.  
 
Necrosis occurred rapidly and was restricted to the center of the lesion 
The presence of necrosis was investigated by both Western blot and electron 
microscopy. Western blots against fodrin were performed to investigate the 
involvement of calpain. The calpain-specific (150 kDa) band increased rapidly 
and lastingly after ischemic injury (Figure S2A, B). Already at the moment of 
reperfusion, it had almost tripled (289% ± 42) compared to control, and then it 
further increased to its maximum value at 12h (645% ± 86), thereafter remaining 
stable (647% ± 46 at 24h). 
At the electron microscopic level, ultrathin sections of cortical regions 
localized in the center of the lesion showed dying neurons with necrotic 
morphology. At 24h after the beginning of reperfusion, dying neurons with 
swollen cell bodies (Figure S2F) and neurites (Figure S2G) were detected in the 
center of the lesion. These neurons displayed an increase in their cytoplasmic 
volume (but with loss of structured content), plasma membrane disruption 
(arrows) and at high magnification showed dilated organelles (such as 
mitochondria and endoplasmic reticulum) (Figure S2I) as compared to a control 
neuron (Figure S2D, E, H). However, there was little sign of chromatin 
condensation in the nucleus. 
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 Supplementary figure legend 
 
Figure S1: Evolution of the brain lesion over time following focal ischemia 
at P12.  
Representative cresyl-violet stained coronal sections at the level of the 
hippocampus 5h (A), 24h (B), 7days (C) and 28 days (D) after reperfusion. Bar: 
0.5 mm. (E) Lesion volume was assessed by measuring pale areas in cresyl 
violet-stained sections. Tissue loss was expressed in mm3: 5h (13.6±5.8, n=5); 
12h (37.7±10.4); 24h (55.1±4.8, n=9); 7 days (37.2±5.6, n=3); 14 days 
(23.5±13.3); 28 days (13.3±2.8, n=4). Data represent mean ±SEM. (F) 
Distribution of infarct area plotted as a function of anterior-to-posterior distance 
5h, 12h and 24h after reperfusion. The increase in lesion volume occurred earlier 
in the more anterior parts.  
 
Figure S2: Calpain involvement and necrosis following cerebral ischemia at 
P12. 
(A) Representative immunoblot of calpain-dependent fodrin cleavage in ischemic 
cortex extracts after 0h, 2h, 6h, 12h and 24h of reperfusion. The tubulin bands 
confirm equal loading. (B) Quantification of calpain-specific fodrin cleaved 
product in homogenates of ischemic cortex after 0h, 2h, 6h, 12h and 24h (n>5 
per group). The 150 kDa calpain-specific fodrin cleaved product showed a 
significant increase already at the moment of reperfusion (0h) and then increased 
progressively to reach its maximum value at 12h post-reperfusion. (C) 
Quantification of caspase-specific fodrin cleaved product in the same 
homogenates after 0h, 2h, 6h, 12h and 24h (n>5/group). The 120 kDa caspase-
3-specific fodrin breakdown product significantly increased from 6h to 24h after 
the beginning of the reperfusion. Data represents mean ±SEM. Comparisons by 
t-test with control (unoperated) rat cortex: *, p < 0.05; **, p < 0.01. (D-I) Electron 
micrographs showing the involvement of necrosis in the center of the lesion at 
24h post-reperfusion but not in the non-ischemic hemisphere. Control neuron 
showing normal morphology of its cell body (including the nucleus, n) (D) and 
neurites (E). (H) High magnification of control neuron’s cytoplasm with 
mitochondria (m) and endoplasmic reticulum (er). Dying neuron located at the 
center of the lesion (F) and neurites (G). High magnification of its cytoplasmic 
content (I). Bars: D, F = 5µm; E, G = 1µm; H, I = 200nm. 
 
Figure S3: Relationship between autophagic and apoptotic pathways after 
cerebral ischemia at P12.  
Double labeling for cleaved caspase-3 (red; A-D) with LAMP1 (green; A’-B’) or 
cathepsin D (green; C’ and D’) revealed no labeling for caspase-3 in cathepsin D 
or LAMP1 rich areas (C’’ and B’’) and no labeling for cathepsin D or LAMP1 in 
caspase-3 rich areas (A’’ and D’’). Double labeling for cleaved caspase-9 (red; 
E-H) with LAMP1 (green, E’ and F’) or cathepsin D (green, G’ and H’) likewise 
showed no colocalization in caspase-9 rich areas (E’’ and G’’) or cathepsin D or 
LAMP1 rich areas (G’’ and F’’). Confocal microscopy. Bars: 50µm. 
 



